Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients

Diabetes

Volumn 54, Issue 10, 2005, Pages 2961-2967

  Weekers, Laurent ^a   Bonhanick, Béatrice ^b   Hadjadj, Samy ^c   Gallois, Yves ^d   Roussel, Ronen ^e,f   Pean, Franck ^f   Ankotche, Amos ^e   Chatellier, Gilles ^g   Alhenc Gelas, François ^f   Lefebvre, Pierre J ^a   Marre, Michel ^e,f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU RANGUEIL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d Universite d'Angers   (France)

^e BICHAT HOSPITAL   (France)

^f INSERM   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; RAMIPRIL;

ADULT; ALLELE; ARTERY RESISTANCE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION;

ADULT; ALBUMINURIA; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; FEMALE; GENE DELETION; GENOTYPE; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HUMANS; HYPERGLYCEMIA; KIDNEY; MALE; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RAMIPRIL; RENIN;

EID: 25844525569     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.54.10.2961     Document Type: Article

References (46)

1. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH: Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. Br Med J 313:779-784, 1996
2. Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72:375-380, 1982
3. Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Tripoddo NC: Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 233:F366-F372, 1977
4. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion deletion polymorphism in angiotensin I conversion enzyme accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346, 1990
5. Marre M, Chatellier G, Leblanc H, Guyenne TT, Menard J, Passa P: Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 297:1092-1095, 1988
6. Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
7. ACE Inhibitors in Diabetic Nephropathy Trialist Group: Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134:370-379, 2001
8. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B: Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54:1238-1244, 2005
9. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol 12:541-549, 2001
10. Rudberg S, Rasmussen LM, Bangstad H-J, Osterby R: Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 23:544-548, 2000
11. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow-up study. Br Med J 313:591-594, 1996
12. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong L-A, Fuller JH, EUCLID Study Group: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. Diabetes 47:1507-1511, 1998
13. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19:410-415, 1981
14. Marre M, Bouhanick B, Berrut G, Gallois Y, Le Jeune JJ, Chatellier G, Menard J, Alhenc-Gelas F: Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Hypertension 33:775-780, 1999
15. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group, J Clin Invest 99:1585-1595, 1997
16. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
17. Tarnow L, Gluud C, Parving HH: Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13:1125-1130, 1998
18. Marre M, Hallab M, Billiard A, Le Jeune JJ, Bled F, Girault A, Fressinaud P: Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 18 (Suppl. 2):S165-S168, 1991
19. O'Hare P, Bilous R, Mitchell T, O'Callaghan CJ, Viberti GC: Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 23:1823-1829, 2000
20. Thuillez C, Richer C, Giudicelli JF: Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers. Am J Cardiol 59:38D-44D, 1987
21. White NH, Skor D, Santiago JV: Practical closed-loop insulin delivery: a system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin-dependent diabetics. Ann Intern Med 97:210-213, 1982
22. Visscher CA, de Zeeuw D, de Jong PE, Sluiter WJ, Huisman RM: Drug-induced changes in renal hippurate clearance as a measure of renal blood flow. Kidney Int 48:1617-1623, 1995
23. Danilov S, Savoie F, Lenoir B, Jeunemaitre X, Azizi M, Tarnow L, Alhenc-Gelas F: Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies. J Hypertens 14:719-727, 1996
24. Menard J, Guyenne TT, Corvol P, Pau B, Simon D, Roncucci R: Direct immunometric assay of active renin in human plasma. J Hypertens 3 (Suppl.):S275-S278, 1985
25. Pham-Huu-Trung MT, Corvol P: A direct determination of plasma aldosterone. Steroids 24:587-588, 1974
26. Marre M, Claudel JP, Ciret P, Luis N, Suarez L, Passa P: Laser immunonephelometry for routine quantification of urinary albumin excretion. Clin Chem 33:209-213, 1987
27. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352:1252-1256, 1998
28. Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardio-vascular events in high-risk patients. N Engl J Med 342:145-153, 2000
29. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
30. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). Br Med J 328: 495, 2004
31. Miller JA, Scholey JW, Thai K, Pel YP: Angiotensin converting enzyme gene polymorphism and renal hemodynamic function in early diabetes. Kidney Int 51:119-124, 1997
32. Luik PT, Hoogenberg K, Kerstens MN, Beusekamp BJ, De Jong PE, Dullaart RP, Navis GJ: The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric type 1 diabetes mellitus. Diabetologia 46:1131-1139, 2003
33. Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J: Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942, 1995
34. Osei SY, Price DA, Laffel LM, Lansang MC, Hollenberg NK: Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 36:122-126, 2000
35. Miller JA: Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10:1778-1785, 1999
36. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
37. Ito S, Arima S, Ren YL, Juncos LA, Carretero OA: Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91:2012-2019, 1993
38. Pieper GM: Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension 31:1047-1060, 1998
39. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia Inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348, 2001
40. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 100:678-684, 1997
41. Ruschitzka F, Noll G, Luscher TF: Angiotensin converting enzyme inhibitors and vascular protection in hypertension. J Cardiovasc Pharmacol 34 (Suppl. 1):S3-S12, 1999
42. Chobanian AV, Hope S, Brecher P: Dissociation between the antiatherosclerotic effect of trandolapril and suppression of serum and aortic angiotensin-converting enzyme activity in the Watanabe heritable hyperlipidemic rabbit. Hypertension 25:1306-1310, 1995
43. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW: Nephropathy in diabetes. Diabetes Care 27 (Suppl. 1):S79-S83, 2004
44. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
45. DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703-1720, 1995
46. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving HH: Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26:1501-1506, 2003